RB-HBV008 / Suzhou Ribo - LARVOL DELTA

Ionizable liposomal siRNA therapeutics enables potent and persistent treatment of Hepatitis B. (PubMed, Signal Transduct Target Ther) - "In addition, according to the requirements of Investigational New Drug (IND) application, a potent siRNA targeting hepatitis B virus (HBV) was selected and encapsulated with RBP131 to fabricate a therapeutic formulation termed RB-HBV008...In contrast, entecavir (ETV), the first-line clinically-employed nucleoside analog drug, barely recused the antigen expression, although it triggered as high as 3.50 log reduction of viral DNA, in line with clinical observations. Moreover, the toxicity profiles suggested satisfactory safety outcomes with ten times the therapeutic window. Therefore, this study provides an effective nucleic acid delivery system and a promising RNAi agent for the treatment of hepatitis B."

Journal • Hepatitis B • Hepatology • Infectious Disease • Inflammation • APOB